Travere Therapeutics

Travere Therapeutics is the rare-kidney-disease biotech that pivoted from a deeply unprofitable specialty-pharma model into a single-product growth story over the last twenty-four months. The transformation is binary: FILSPARI (sparsentan), a once-daily oral dual endothelin and angiotensin receptor antagonist, received full FDA approval for IgA nephropathy in late 2024 after an accelerated-approval-to-full-approval pathway. Annualized revenue run-rate has gone from roughly 60 million USD in early 2024 to approximately 360 million USD currently — and the stock has tripled from a 13.88 USD low to 42.59 USD today.

The clinical case is unusually strong. IgA nephropathy is the most common form of glomerulonephritis worldwide, affecting roughly 130 thousand US patients with severe-progression risk. Until 2023, the only treatments were supportive care (renin-angiotensin inhibition) and chronic immunosuppression. FILSPARI demonstrated 50% reduction in proteinuria versus losartan in the PROTECT Phase 3 trial, plus a meaningful preservation of kidney function (eGFR slope) — the FDA endpoint that historically required ten-year mortality trials. That eGFR data is what unlocked the full-approval upgrade and the rapid uptake.

The second product is Thiola and Thiola EC for cystinuria — a smaller orphan asset generating approximately 130 million USD annually with stable demand and minimal competitive threat. The pipeline beyond these two is thin: Pegtibatinase for homocystinuria (Phase 3 readout 2026), plus collaboration assets with limited near-term commercial impact.

The story for 2026-2027 is whether FILSPARI uptake decelerates as initial high-risk patients are treated, or whether the addressable market expands as nephrologists become comfortable using it earlier in the disease course. Bull case: 700 million USD peak in IgA nephropathy alone. Bear case: 300-400 million USD plateau.

Institutional ownership has consolidated into rare-disease specialists. Q1/2026 13F: Vivo Capital at 9.4% (long-time holder since 2019, added through the 2023-2024 trough), Federated Hermes at 4.8%, Frazier Healthcare Partners at 4.1% (built position during the PROTECT readout in 2023). Index ownership (Vanguard 9%, BlackRock 8%) is the standard small-cap-biotech passive base.

Insider activity has been net-buying: CEO Eric Dube purchased 480 thousand USD between October 2024 and February 2026 at prices ranging from 16-32 USD. CMO Jula Inrig has retained 100% of vested options. CFO Christopher Cline executed a 250-thousand-USD planned sale in March 2026 but the offset insider buying makes the aggregate net positive.

Short interest is the most striking signal: 19.99% of float with days-to-cover of 8.4 — one of the highest in mid-cap biotech. The bear thesis combines (a) launch-curve fade after high-risk-patient saturation, (b) competitive risk from Calliditas Therapeutics Tarpeyo and Novartis iptacopan in the IgA nephropathy market, and (c) ongoing operating losses requiring near-term capital raise. The setup is genuinely two-sided — but the squeeze potential on a clean Q2/2026 prescription-trend beat is meaningful.

Travere is in the early stages of a profitability inflection where forward multiples matter more than trailing. Forward P/E of 8.5x looks attractive but assumes 2027 consensus EPS of 4.20 USD materializes — that requires FILSPARI revenue of ~540 million USD plus operating leverage on a flat cost base. EV/EBITDA at 258x is meaningless given the small EBITDA base; on 2027 consensus EBITDA of ~130 million USD, the forward multiple drops to ~30x — at the high end of rare-disease peers (Ultragenyx, Amicus, BioMarin cluster 20-30x).

Risk-adjusted NPV by sell-side averages 48-56 USD per share at base case (FILSPARI peak 600 million USD, Thiola steady, pipeline modest), 62-78 USD at bull case (FILSPARI peak 800 million USD plus positive pegtibatinase). Bear case 28-36 USD if FILSPARI plateaus at 400 million USD. Current 42.59 USD sits at the low end of the base case range — modest upside on continued execution, meaningful downside if launch saturation arrives earlier than bulls model.

Price-to-sales of 7.4x is high for a healthcare company but in line with rare-disease growth biotechs at similar profitability inflections. Debt-to-equity of 332 normalizes once GAAP profitability arrives and retained earnings begin to accumulate — within 3-4 years the ratio could return to under 100. Free cash flow yield is negative; the thesis is operating leverage, not current cash distribution.

1. August 2026: Q2 2026 earnings — first quarter likely to confirm Q1/2026 acceleration is sustained
2. Q4 2026: Pegtibatinase Phase 3 readout for homocystinuria — pipeline diversification opportunity
3. Q3-Q4 2026: First quarterly GAAP-positive print — sentiment inflection independent of revenue

Travere is the cleanest rare-disease launch story of 2026 with the cleanest set of two-sided arguments. The FILSPARI uptake numbers are real, the IgA nephropathy market is large enough to support a sustained run-rate, and the GAAP-profit inflection coming in late 2026 will probably trigger a positive rerating regardless of pegtibatinase outcome. The bear case (short interest 20%) is also real but feels more like positioning than structural — once Q2 confirms Q1, a meaningful portion of the short base covers.

My personal approach for binary-launch names like this is sizing of 1-2% with a stop placed below the 200-day moving average (currently 30 USD) and add-on capacity reserved for the Q2/2026 earnings beat. Buying the print after a confirmed beat is historically a better return than buying ahead of it for short-squeeze candidates. Target 60-65 USD on a clean execution path through 2027, with the upside lever being pegtibatinase optionality. Not a buy-and-forget — this is an 18-month thesis with active position management.